Amgen (NQ:AMGN)

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗

September 25, 2024

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...

Via Benzinga

Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday? ↗

September 24, 2024

Regeneron filed an appeal after a court's decision, which was issued under seal.

Via Benzinga

Market Whales and Their Recent Bets on AMGN Options ↗

September 24, 2024

Via Benzinga

What the Options Market Tells Us About Amgen ↗

September 23, 2024

Via Benzinga

Interesting Technical Analysis finding for AMGEN INC (NASDAQ:AMGN) ↗

September 20, 2024

NASDAQ:AMGN Shows Potential for a Breakout.

Via Chartmill

Where Will Amgen Be in 5 Years? ↗

September 20, 2024

There are plenty of ongoing positive developments with the biotech giant.

Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.

2 Weight-Loss Stocks That Could Rocket Higher This Year ↗

September 24, 2024

The EV giant, once a big S&P 500 laggard in 2024, is now up for the year.

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling ↗

September 23, 2024

Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off.

Topics Stocks

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea ↗

September 23, 2024

These two stocks could be rivals in the intense GLP-1 space in the future.

Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy? ↗

September 23, 2024

Are Verizon, Amazon, Cisco, Amgen, and the S&P Biotech Bull 3X Shares ETF poised to make your portfolio skyrocket? In this video, I take a closer look.

Can These 5 Assets Skyrocket Your Portfolio? ↗

September 22, 2024

Being able to recite the potential problems in the world does not make you a good investor.

Topics ETFs Stocks

Behind the Scenes of Amgen's Latest Options Trends ↗

September 19, 2024

Via Benzinga

(AMGN) - Analyzing Amgen's Short Interest ↗

September 03, 2024

Via Benzinga

Amgen Unusual Options Activity For August 29 ↗

August 29, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 18, 2024

Via Benzinga

The Bull Market Strengthened, Let The Naysayers Say Nay... ↗

September 15, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Growth-oriented businesses can make excellent additions to a well-diversified portfolio.

Topics ETFs

2 Unstoppable Growth Stocks to Buy Right Now for Less Than $500 ↗

September 13, 2024

Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now ↗

September 12, 2024

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars ↗

September 11, 2024

Via Benzinga

Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival ↗

September 10, 2024

The results are also promising for the next-generation version of that drug.

The current leadership in the stock market is clearly not tech, or the Magnificent 7.

Growth At Any Price (GAAP) Is A Bad Strategy. Valuation Matters. ↗

September 08, 2024

Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected.

Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern ↗

September 05, 2024

Via Benzinga

Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗

September 03, 2024

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...

Via Benzinga

Topics Economy

Patchy But Still Bullish ↗

September 02, 2024

Two weeks ago we turned to a more bullish stance, which has proved to be correct, though we still await the explosive movement out of these consolidations.

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Jason Snipe of Odyssey Capital Advisors likes Intuit Inc., after the company beat on the top and bottom lines, but missed on guidance.

Intuit, Amgen And Sprott Uranium Miners ETF: CNBC's 'Final Trades' ↗

August 29, 2024

Via Benzinga

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug ↗

August 27, 2024

The single-dose vials will also increase supply, the drug giant says.